Hengrui Medicine (01276): SHR-A2009 and Adalimumab injection have obtained the clinical trial approval notification.

Zhitong Finance APP News: Heng Rui Medicine (01276) announced that recently, its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (referred to as "National Medical Products Administration") for the injection of SHR-A2009 and Adeb-eli monoclonal antibody injection, and clinical trials will be conducted soon.